Co-Tareg 80, Co-Tareg 160, Co-Tareg 160 80/12.5, 160/12.5, 160/25 mg FC tablets.
PDF Leaflet Revision Date: 12 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate hypertension.
Dosage (summary)
1 tablet daily; max 320/25 mg.
Onset of Action / Duration
Onset: 2 hours, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause congenital abnormalities.
Key Drug Interactions
- Lithium
- NSAIDs
- Potassium supplements
Contraindications
- Hypersensitivity
- Severe renal impairment
- Pregnancy
- Lactation
Common side effects
- Hypotension
- Hypokalaemia
- Dizziness
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any skin changes
Serious warnings
- Risk of non-melanoma skin cancer
- Dual blockade of RAAS contraindicated
Important Disclaimer
The Co-Tareg 80, Co-Tareg 160, Co-Tareg 160 80/12.5, 160/12.5, 160/25 mg FC tablets. professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
